Related Experiment Video
Updated: Jun 29, 2025
Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Novel Biomarkers in Evaluating Cardiac Function in Patients on Hemodialysis-A Pilot Prospective Observational Cohort
Lazar Chisavu1,2, Viviana Mihaela Ivan1,3, Adelina Mihaescu1,2
1Centre for Molecular Research in Nephrology and Vascular Disease, Faculty of Medicine 'Victor Babes', 300041 Timisoara, Romania.
Insights
Novel biomarkers like interleukin 1-beta show promise in assessing cardiovascular disease in hemodialysis patients. These findings could improve risk stratification and therapeutic interventions for this high-risk population.
Area of Science:
- Nephrology
- Cardiology
- Biomarker Discovery
Background:
- Patients undergoing hemodialysis for chronic kidney disease face significant cardiovascular morbidity and mortality.
- There is a critical need for new biomarkers to identify at-risk individuals and guide therapeutic strategies.
Purpose of the Study:
- To investigate the correlation between novel serum biomarkers and cardiac function/structure in hemodialysis patients.
- To explore the potential of these biomarkers in assessing cardiovascular disease in this population.
Main Methods:
- A prospective observational cohort study involving 77 hemodialysis patients.
- Measurement of serum plasma levels of interleukin 1-beta, galectin 3, human suppression of tumorigenicity factor 2, bone morphogenetic protein 2, and fibroblastic growth factor 23.
- Echocardiographic evaluation of cardiac function and structure.
Main Results:
- Interleukin 1-beta positively correlated with ejection fraction and global longitudinal strain, and negatively with left atrium and left ventricle diameters.
- Galectin 3 showed negative correlations with aortic valve fibrosis and mitral valve calcifications.
- Human suppression of tumorigenicity factor 2 was negatively correlated with mitral valve calcifications.
Conclusions:
- Certain novel biomarkers, including interleukin 1-beta and galectin 3, demonstrate potential for cardiovascular risk assessment in hemodialysis patients.
- These biomarkers may aid in better evaluating cardiovascular disease and informing treatment decisions for individuals on maintenance hemodialysis.
Abstract:
Chronic kidney disease patients treated by hemodialysis present a high cardiovascular morbidity and mortality. There is an imperative need for novel biomarkers for identifying these patients and to offer possible therapeutically interventions. We performed a prospective observational cohort study on 77 patients in the period of October 2021-October 2023. We measured serum plasma levels of interleukin 1-beta, galectin 3, human suppression of tumorigenicity factor 2, bone morphogenetic protein 2 and fibroblastic growth factor 23 at the inclusion site. We evaluated the correlations of these biomarkers with cardiac function and structure evaluated by echocardiography. The mean age was 61.02 (±11.81) years, with 45 (56.2%) males and with a dialysis vintage of 4.95 (2.4-7.8) years. Median ejection fraction was 51 (43-54%), and more than two-thirds of the patients presented valvular calcifications. Overall mortality was 22%. Interleukin 1-beta was correlated positively with ejection fraction and global longitudinal strain and negatively with left atrium diameter and left ventricle telesystolic diameter. Galectin 3 values were negatively correlated with aortic valve fibrosis and mitral valve calcifications, and human suppression tumorigenicity factor 2 was negatively correlated with mitral valve calcifications. Some of these novel biomarkers could be used to better assess cardiovascular disease in patients on maintenance hemodialysis.
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:17Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
01:22Heart Failure Drugs: Diuretics
01:27Dialysis
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...